IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
118.23
-0.14 (-0.12%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close118.37
Open118.19
Bid0.00 x 1200
Ask0.00 x 800
Day's Range117.47 - 118.36
52 Week Range100.22 - 119.30
Volume1,258,900
Avg. Volume2,457,080
Net Assets8.88B
NAV109.77
PE Ratio (TTM)4.11
Yield0.29%
YTD Return3.00%
Beta (3y)1.49
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • Drug pricing debate could heat up in July
    CNBC Videos13 days ago

    Drug pricing debate could heat up in July

    CNBC's Meg Tirrell reports on drug prices and hikes that have already occurred this month. With Michael Yee, Jefferies.

  • MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus
    Yahoo Finance Video2 months ago

    MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus

    Yahoo Finance's Seana Smith on midday market action.

  • Trump lets drug companies off the hook
    Yahoo Finance Video2 months ago

    Trump lets drug companies off the hook

    Trump's plan to lower drug prices does not call for the one move many experts believe would be most effective: A new law that would allow Medicare to negotiate with pharmaceutical providers.

  • Yahoo Finance Contributors2 months ago

    Stock Market Analysis 5/11/18

  • InvestorPlace9 days ago

    Trump Tweets Threat to Pfizer but Investors Shrug it Off

    Pfizer (NYSE:PFE) was the target of a Presidential tweet tantrum Monday over its second price hike of the year but investors shrugged it off.

  • ETF Trends13 days ago

    Biotech ETFs Climb on Biogen’s Promising Clinical Trial

    Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...

  • InvestorPlace13 days ago

    Don’t Buy Biogen Stock on the Promise of an Alzheimer’s Breakthrough

    Biogen (NASDAQ:BIIB) is the hot stock of the moment thanks to success in a trial of an Alzheimer’s drug. Progress on Alzheimers makes Biogen stock worth at least a look, right? Both follow the so-called “amyloid hypothesis,” the idea that reducing amyloid plaques using monoclonal antibodies can reverse the disease.

  • MarketWatch13 days ago

    Biotech ETFs surge, lifted as Biogen sees best session in more than a decade

    MARKET PULSE Exchange-traded funds that track the biotechnology sector jumped on Friday, supported by a huge gain in industry bellwether Biogen, which climbed after a positive drug trial. The iShares Nasdaq Biotechnology ETF (IBB) jumped 2.

  • TheStreet.com13 days ago

    Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

    First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.

  • Go Long Pfizer Stock — It’s an Easy Pill to Swallow
    InvestorPlace14 days ago

    Go Long Pfizer Stock — It’s an Easy Pill to Swallow

    Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.

  • It May Be Imperfect, but Celgene’s Growth Is Worth Taking Note of
    InvestorPlace14 days ago

    It May Be Imperfect, but Celgene’s Growth Is Worth Taking Note of

    Are shares of Celgene Corporation (NASDAQ:CELG) finally bottoming? Without news flow for the stock to react on, it’s hard to confirm whether the peak-to-trough drop of 49.6% in CELG stock is over or if more losses are still to come. Celgene is far from perfect.

  • Why Axovant Sciences Stock Jumped ~160% on Wednesday
    Market Realistlast month

    Why Axovant Sciences Stock Jumped ~160% on Wednesday

    Axovant Sciences (AXON) is a clinical-stage biopharmaceutical company. The company’s stock price jumped ~160.0% to the closing price of $4.55 on June 6 due to several factors. Axovant Sciences stock price has increased by ~137.0% in the last three trading sessions.

  • Benzinga2 months ago

    Analysis: White House Takes Bully Pulpit Approach On Drug Pricing Reform, Congress Unlikely To Act

    President Donald Trump is keeping pharmaceutical execs, lobbyists and investors on their toes. “[The notice] is consistent with his administration's ‘bully pulpit’ strategy of cajoling the drug makers into industry-led changes to drug pricing,” Height analyst Andrea Harris said in a note.

  • Trade of the Day: Amgen, Inc. Clears a Breakout Hurdle
    InvestorPlace2 months ago

    Trade of the Day: Amgen, Inc. Clears a Breakout Hurdle

    While so doing, some of the larger biotech names in the space, such as Amgen, Inc. (NASDAQ:AMGN), broke past key near-term technical resistance. This now sets up bullish trades for AMGN stock. Each time I discuss a biotechnology stock in this column I must also point out that these stocks, even the large ones, can be volatile and prone to sharp price movements in either direction.

  • Analysts’ Recommendations for Incyte in May
    Market Realist2 months ago

    Analysts’ Recommendations for Incyte in May

    Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.

  • 2 ETFs to Help You Build Retirement Wealth
    Motley Fool2 months ago

    2 ETFs to Help You Build Retirement Wealth

    These exchange-traded funds could deliver outsize gains in the years ahead.

  • Biotech ETFs Are the Best Way to Play the Recovering Sector
    InvestorPlace2 months ago

    Biotech ETFs Are the Best Way to Play the Recovering Sector

    The summer of 2015 marked the end of the glory years in the biotechnology sector. The biotech valuation correction that lasted over two years may be coming to an end. Some well-known, large-cap names — such as AbbVie Inc (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) — are currently trading at forward P/E multiples in the 10+ range.

  • Investopedia2 months ago

    Biotech Stocks Could Lead Summer Rally

    Biotech stocks turned higher on May 11 after President Trump outlined a series of steps the administration might take to control skyrocketing drug prices. The lack of details triggered a relief rally underpinned by skepticism that the initiatives will pass Congress and their deep reliance on industry contributions.

  • How Ionis’s Spinraza Did in Q1
    Market Realist2 months ago

    How Ionis’s Spinraza Did in Q1

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.

  • Analyzing ABMD, BR, and TFX Stocks
    Market Realist2 months ago

    Analyzing ABMD, BR, and TFX Stocks

    Abiomed’s (ABMD) net income has grown at a three-year and five-year average of 95.1% and 120.4%, respectively. The company’s pre-tax margin grew from 10.7% in 2013 to 20.5% in 2017. ABMD beat the medical device industry and the S&P 500 between 2013 and 2017. The market cap gained 680% between 2013 and 2017.

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist2 months ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • InvestorPlace2 months ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • InvestorPlace2 months ago

    Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock has been decimated over the years. This morning the stock is rallying on the news that the famed investor Warren Buffett doubled his stake in Teva stock. Wall Street loves to chase Buffett’s investments.

  • 5 Top Stock Trades for Monday Morning
    InvestorPlace2 months ago

    5 Top Stock Trades for Monday Morning

    On Friday, stocks digested the big rally over the past week, with many names trading in a rather tight range. That’s something we haven’t seen in a while, with markets more volatile in 2018 vs 2017. In any regard, here are the top stock trades we’re watching for this week.Top Stock Trades for Monday #1: Nvidia (NVDA)